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THE CLINICAL USE OF CORD BLOOD-DERIVED VIRUS-SPECIFIC
CYTOTOXIC T LYMPHOCYTES REACTIVE AGAINST CYTOMEGALOVIRUS
(CMV), ADENOVIRUS, AND EPSTEIN-BARR VIRUS (EBV)
Hanley, P.J.1,2, Martinez, C.1, Leung, K.1, Cruz, C.R.Y.1, Savoldo, B.1,
Leen, A.M.1, Dotti, G.1,2, Liu, H.1, Gee, A.P.1, Rooney, C.M.1,2,
Krance, R.A.1, Heslop, H.E.1, Shpall, E.J.3, Bollard, C.M.1,2 1Baylor Col-
lege of Medicine, Houston, TX; 2Baylor College of Medicine, Houston, TX;
3University of Texas MD Anderson Cancer Center, Houston, TX
CMV, Adenovirus (Ad) and EBV are viral pathogens causing mor-
bidity and mortality in patients after hematopoietic stem cell trans-
plantation (HSCT) and cord blood transplantation (CBT). We have
shown that adoptive immunotherapy with peripheral blood donor-
derived multivirus-specific Cytotoxic T Lymphocytes (mCTL) di-
rected against EBV, CMV and Ad can effectively prevent and treat
the clinical manifestations of these viruses after HSCT. We have
now extended these studies by expanding mCTL from umbilical
cord blood (CB) to restore cellular immunity to CMV, EBV and Ad
simultaneously after CBT. However, the development of mCTL for
patients undergoing CBT requires the priming and extensive expan-
sion of na€ıve T cells rather than the more limited and simple direct
expansion of pre-existingmemoryT cell populations from virus-expe-
rienced donors. We have developed a novel protocol utilizing an ini-
tial round of stimulation with autologous CB-derived dendritic cells
transduced with a recombinant Ad5f35 vector carrying a transgene
for the immunodominant CMV antigen, pp65 (Ad5f35pp65) in the
presence of IL12, IL15 and IL7. This is followed by 2 rounds of
weekly stimulation with autologous EBV-LCL transduced with the
same vector in the presence of IL15 and IL2. After 3 rounds of stim-
ulation, 2 CTL cultures generated for clinical use contained amean of
48% (range 24-72%) CD81, and 42% (range 11-72%) CD41 cells
with mean 30.5% (range 23-46%) CD45RA-/CD62L1 T cells. In
51Cr release and/or IFN-g ELISPOT assays, both mCTL lines
showed specific activity against CMV, EBV and Ad targets. So far
we have treated 2 patients in this phase I study, both on dose level 1
(5x106/m2). Patients received 1 infusion of CTL on day 63 post-
CBT. Only patient 1 is currently evaluable as patient 2 was infused
too recently to test. We observed a 10-fold increase in CMV-specific
T cells 5 weeks-post CTL. This patient was transiently positive for
CMV by PCR at 4 weeks post CTL but was negative within 16
days of receiving a second dose of mCTL with a corresponding rise
in CMV-specific CTL detected in the peripheral blood. The patient
became Ag1 for Ad in his stool associated with diarrhea which
resolved spontaneously without additional therapy. In summary, we
have developed a protocol for the generation of mCTL from CB: in-
fusion of small numbers of these cells increased virus-specificT cells in
the peripheral blood post CTL infusion dramatically earlier than
observed immune reconstitution post CBT.
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DRAMATIC REGRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA IN
THE FIRST PATIENT TREATED WITH DONOR-DERIVED GENETICALLY-
ENGINEERED ANTI-CD19-CHIMERIC-ANTIGEN-RECEPTOR-EXPRESSING
T CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Kochenderfer, J.N.1, Dudley, M.E.2, Maric, I.3, Feldman, S.A.2,
Salit, R.1, Hardy, N.M.1, Layton, P.1, Blacklock-Schuver, B.1,
Wilder, J.1, Devillier, L.2, Gress, R.E.1, Morgan, R.A.2,
Rosenberg, S.A.2, Bishop, M.R.1 1National Cancer Institute, Bethesda,
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We have initiated a clinical trial in which patients receive infusions
of allogeneic T cells that are genetically modified with a gammaretro-
viral vector to express a chimeric antigen receptor (CAR) that recog-
nizes the B-cell antigen CD19. The first patient treated on this trial
was a 65 year-old man with chronic lymphocytic leukemia (CLL)
who relapsed after HLA-matched unrelated donor hematopoietic
stem cell transplantation. Following the relapse, the patient received
4 donor lymphocyte infusions (DLIs) with a maximum CD31 cell
dose of 2.9x107/kg and then a second stem cell transplant from the
original donor. An objective remission of the leukemia did not occur
after any of the DLIs or the second transplant. Five months after the
second transplant, whenhisCLLwas progressing, the patient received
an infusion of 6.2x107 (1x106 cells/kg) allogeneic anti-CD19-CAR-transduced T cells derived from his unrelated transplant donor.
Thirty-nine percent of the infused cells expressed the anti-CD19
CAR, and the cells produced interferong and IL-2 in a CD19-specific
manner. The patient did not receive any other therapy in conjunction
with the CAR-transduced T cells. From 6 to 12 days after the CAR-
transduced T cell infusion, the patient experienced fevers, fatigue,
mild hypoxemia, and intermittent mild hypotension. Increases in se-
rummagnesium, phosphorous, and uric acid consistent with tumor ly-
sis syndrome occurred. A decrease in cardiac left ventricular function
developed, which was improving at last follow-up. The patient’s blood
B cell count decreased from 286 cells/mL before the CAR-transduced
T cell infusion to 0 cells/mL 26 days after the cell infusion. Before the
CAR-transduced T cell infusion, CLL cells made up 80-90% of the
patient’s hypercellular bone marrow. A bone marrow biopsy per-
formed 26 days after the cell infusion showed a normocellularmarrow,
nearly absent B-lineage cells, and no evidence of CLL. CT scans re-
vealed a greater than 50%decrease in the size ofmultiple lymph nodes
after theCAR-transducedT cell infusion, but residual adenopathywas
present. CAR-transduced cells were not detected in the patient’s
blood by quantitative PCR during the first week after the T cell infu-
sion, but made up 0.98% of blood mononuclear cells 11 days after the
infusion. These results are encouraging for further development of
anti-CD19-CAR-expressing T cells as a treatment for relapse after
allogeneic stem cell transplantation.
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ALLOGENEIC VIRUS-SPECIFIC T CELLS WITH HLA ALLOREACTIVITY DO
NOT PRODUCE GRAFT-VERSUS-HOST DISEASE IN HUMAN SUBJECTS
Melenhorst, J.J.1, Leen, A.M.2, Bollard, C.M.2, Quigley, M.F.3,
Price, D.A.3, Rooney, C.M.2, Brenner, M.K.2, Barrett, A.J.1,
Heslop, H.E.2 1National Heart, Lung, and Blood Institute, Bethesda,
MD; 2Baylor College of Medicine, Houston, TX; 3National Institute of
Allergy and Infectious Diseases, Bethesda, MD
We and others have recently established that T cell reactivity with
non-self HLA (HLA alloreactivity) arises not only from naive T cells
but also from the antigen-experienced T cell pool, including Epstein-
Barr virus (EBV) and cytomegalovirus (CMV)-specific T cells. Virus-
specific T cells could therefore mediate graft-versus-host disease
(GvHD) if infused into partially HLA mismatched recipients. We
reviewed our clinical experience with adoptive transfer of allogeneic
hematopoietic stem cell transplant donor-derived virus-specific T
cell lines in 153 recipients, including 73 partially HLA-mismatched
recipients. The degree of HLA mismatching varied from one allele
to a full haplotype. De novo GvHD did not develop after infusion of
cytotoxic T lymphocytes (CTL), and the incidence of GvHD reacti-
vation was 6.5% and not significantly different between recipients of
HLA matched or mismatched CTL. Thus, virus-specific CTL did
not mediate GvHD, even in recipients of partially matched CTL.
Next we analyzed the HLA alloreactivity of four donor-infused bivi-
rus-specific T cell lines, using activated T cells, that are known to
lack CMV and EBV antigen expression, as antigen presenting cells
(TAPC). We used a panel of 44 TAPC covering the most frequent
HLA class I and II alleles. The CTL lines were labeled with CFSE
and stimulated with TAPC for 6 hours, after which production of
TNFa and IFNg/IL-2 by CD41 and CD81 T cells in the CFSE-
positive fraction was analyzed by flow cytometry. All CTLs responded
to a number of TAPC, with some APC being recognized strongly.
The majority elicited only weak or no response from the CTLs. We
then assessed whether the CTLs recognized TAPC expressing the re-
cipient’s HLA alleles.We found moderate reactivity of the CTL with
1-5 TAPC expressing recipientHLA alleles. Taken together, our data
indicate that reactivity of virus-specific CTLs with hematopoietic
APC does not correlate with the risk of developing GvHD, and that
virus-specific CTL can safely be infused into HLA class I and/or II
mismatched recipients.
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PHASE I CLINICAL TRIAL TARGETING CD201 NON-HODGKIN’S
LYMPHOMA (NHL) AFTER AUTOLOGOUS STEM CELL TRANSPLANT
WITH ANTI-CD3  ANTI-CD20 BISPECIFIC ANTIBODY ARMED T CELLS
Lum, L.G.1, Thakur, A.1, Ratanatharathorn, V.1, Al-Kadhimi, Z.1,
Paul, E.1, Skuba, C.2, Steel, P.1, Ayash, L.1, Abidi, M.1, Wedge, J.1,
Uberti, J.P.1 1Karmanos Cancer Institute, Detroit, MI; 2College of Veter-
inary Medicine, East Lansing, MI
Oral Presentations S159Relapse rates in patients (pts) after autologous stem cell transplant
(SCT) for high risk or refractoryNHL remains high. Our preclinical
studies showed that activated T cells (ATC) armed with anti-CD3 x
anti-CD20 bispecific antibody (CD20Bi) lyse rituximab-resistant
CD201 lymphoma cells. A phase I trial was conducted in 15 high
risk or refractory NHL pts to determine the safety of armed ATC
(aATC) given after SCT and whether aATC infusions accelerate im-
mune recovery and provide an anti-lymphoma effect. Leukopheresis
products were activated with anti-CD3, expanded in IL-2, armed
with CD20Bi, and cryopreserved for infusions after SCT. At the
time of SCT, there were 6 pts in 1st or 2nd remission (CR), 4 pts
had refractory disease (PRD), 4 pts were in partial response, and 1
pt had progressive disease (PD). Pts received 5-20  109 aATC
per infusion. The first 3 patients received 5x109 three times per
week for 3 weeks and then once per week for 6 weeks for a total
aATC dose of 75x109. Subsequently, the schedule was revised to 1
infusion/week for 4 weeks with infusion doses of 10, 15, and
20x109 aATC. The median dose of CD341 cells/kg infused was
4.0x106(1.04-12.3x106). The ATC product was 92% viable, con-
tainedmedians of 96.5%CD3, 67%CD4, and 48.9%CD8 cells. Fif-
teen pts received aATC and 12 were evaluable for toxicities. The
Table 1 summarizes grade 1-3 events.
Table 1. Grade-1-3 Events
Dose 5 billion 10 billion 15 billion 20 billionPts Number 3 3 3 3
Infusions 15 4 4 4
Fever 3 10 12 12
Chills 2 7 3 4
Malaise 1 2 7 11
Hypotension 3 4 1 5
Tachycardia 3 2 5 4
Nause/vomiting 0 7 3 4
Headache 0 2 2 2
Dyspnea 1 0 0 0
Hypoxia 0 0 0 1(NCI Immunotherapy Criteria).
The median day to engraftment was 14.75 days without G-CSF.
aATC could be detected by flow cytometry up to 12 hours after in-
fusion. The proportions of CD4 cells were in the normal range up to
a month. There was a . 4x increase in the mean (6SD) number of
IFNg EliSpots in response to Daudi cells from 30.5620.5/106
PBL preSCT to 125.66130/106PBL post SCT, p\0.008. The me-
dian cytotoxicity mediated by NK cells ranged from 8.2-13.7% be-
tween 2 weeks and 3 months after SCT. Serum cytokines and
chemokines peaked around 4 hrs after aATC infusions with 1-2
log increases in IL-2, IL-7, IL-15, IL-2r, MIP-1b, IP10, MIP-1a,
MIG, and MICP-10. At 90 days after SCT, 9 pts were in CR and
6 pts had PD. The median OS has not been reached and OS is pro-
jected to be 55% at 4 years. Pts in CR prior to SCT had longer sur-
vival at 85% with no relapses after 1 year after SCT. These findings
show that: 1) ATC can be expanded from heavily pretreated NHL
pts; 2) aATC infusions are safe; 3) induce high levels of serum cyto-
kines and chemokines; and 4) may provide anti-tumor help and cyto-
toxicity after SCT.24
COMBINING AZACITIDINE (VIDAZA, AzA) AND DONOR LYMPHOCYTE
INFUSIONS (DLI) AS FIRST SALVAGE TREATMENT IN PATIENTS (PTS)
WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYN-
DROMES (MDS) RELAPSING AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION (Allo-SCT): INTERIM-ANALYSIS FROM
THE AZARELA-TRIAL (NCT-00795548)
Schroeder, T.1, Czibere, A.G.1, Kr€oger, N.2, Platzbecker, U.3, Bug, G.4,
Uharek, L.5, Luft, T.6, Bruns, I.1, Zohren, F.1, Wolschke, C.2,
Fenk, R.1, Haas, R.1, Kobbe, G.1 1Heinrich Heine University, Medical
Faculty, Duesseldorf, Germany; 2University Cancer Centre, Hamburg,
Germany; 3University Hospital Dresden, Dresden, Germany; 4Universityof Frankfurt, Frankfurt, Germany; 5Charite Campus Benjamin Frank-
lin, Berlin, Germany; 6University of Heidelberg, Heidelberg, Germany
Prognosis for pts with AML/MDS relapsing after allo-SCT is
poor and therapeutic options are limited. Results from recent retro-
spective analyses on the use of Aza1/- DLI in pts with AML/MDS,
who relapsed after allo-SCT, were encouraging.
To evaluate the potential of Aza combined with DLI as 1st sal-
vage therapy in pts with AML/MDS relapsing after allo-SCT we
conducted a prospective phase-II multicenter trial. Pts were al-
lowed to receive up to 8 cycles Aza (100 mg/m2/d d1-5, every 28
d) and 3 DLI with increasing dosages (1-5x106–1-5x108 cells/kg)
after every 2nd Aza cycle. So far, 25 pts (15 f/10 m) are evaluable
for this analysis.
At diagnosis 23 (92%) had AML (15 de novo/8 followingMDS), 1
(4%) MDS (RAEB-1) and 1 (4%) MDS/MPS (CMML-1). Based on
cytogenetics 21 pts belonged to an adverse or intermediate risk
group, whereas 2 pts had favorable cytogenetics (2 n.p.).
At transplant, 6 pts (24%) had induction failure, 6 (24%) suffered
from 1st or 2nd relapse, 10 pts (40%) were in 1st or 2ndCR, while 3 pts
(12%) were untreated. Eight pts (35%) received grafts from MSD
and 15 (65%) from MUD (2 pts missing data). PBSC were used in
24 pts (96%; 1 missing). Prior to relapse 9 (36%) and 3 (12%) pts
had episodes of aGvHD and/or cGvHD, respectively.
At relapse, 4 (31%) of 13 evaluable pts had normal cytogenetics,
while 9 (69%) had chromosomal aberrations including 6 pts (46%)
with complex karyotype. Relapse occurred in median 160 d (range
19-1199) after allo-SCT (BM blasts 34%, range 5-100%, donor
chimerism 63% range 1-100%). Median age was 54 y (range 29-
71). Patients received a median of 3 cycles Aza (range 1-8) and 18
pts (72%) received DLI (median: 1, range 1-4, median CD3 dose
5x106/kg/DLI, range 1-207x106).
Overall response rate was 64% with 5 pts (20%) achieving CR/
CRi, 3 (12%) PR and 8 (32%) SD. Median response duration was
266 d. Acute GvHD occurred in 6 pts (24%) (2 skin/6 liver/ 2 gut)
after a median of 65 d (range 19-179) following the 1st DLI. Three
pts (12%) had limited cGvHD. Hematotoxicity IIIo-IVo was
observed in 64%. Common adverse events were gastrointestinal
side effects and infections. After a median follow-up of 100 d (range
25-485) 15 pts (60%) are alive. Median OS of all pts is 184 d (range
87-281). All pts, who achieved a CR/CRi, remained in ongoing
remission for a median of 229 d.
Our data suggest that salvage therapy with Aza1DLI for pts with
AML/MDS relapsing after allo-SCT is feasible and has significant
anti-leukemic activity in these pts.GRAFT PROCESSING25
A COST EFFECTIVE ANALYSIS OF A RISK-ADAPTED ALGORITHM FOR
PLERIXAFOR USE IN AUTOLOGOUS PERIPHERAL BLOOD STEM CELL
MOBILIZATION
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Lacy, M.Q.1, Ansell, S.M.1, Buadi, F.1, Dingli, D.1, Dispenzieri, A.1,
Litzow, M.R.1, Porrata, L.F.1, Winters, J.L.3, Kumar, S.1 1Mayo Clinic,
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Up to 30% of patients fail to collect minimum numbers of PBSC
for ASCT, and up to 50% of patients fail to collect the optimal num-
ber. Plerixafor, a CXCR4 antagonist, in combination with G-CSF
has shown superior results inmobilizing PBCD341 cells in compar-
ison to G-CSF alone for autologous PBSC mobilization in patients
with NHL or MM. However, due to its high cost, we commenced
a risk adapted algorithm for the utilization of plerixafor starting in
Feb 2009.
Jan-Dec 2008 was the baseline. Patients in upfront mobilization
clinical trials with plerixafor were excluded. From Feb-Nov 2009,
the risk adapted algorithmPlerixafor-1was used. PBSCmobilization
was commenced with G-CSF at 10 mcg/kg/day. If PB CD34 on day
4 or day 5 was$ 10/mL, apheresis was commenced the next morning.
